

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

200.1079CON5

APPLICATION NO

10/057,630

LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT

Ronald M. BURCH et al.

FILING DATE

January 25, 2002

GROUP

1639

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A01	4,690,927	09/01/1987	Voss et al.			
	A02	4,844,907	07/04/1989	Elger et al.			
	A03	4,569,937	02/11/1986	Baker et al.			
	A04	5,190,947	03/02/1993	Riess et al.			


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A05	Friedel et al., "Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," <i>Drugs</i> Vol. 45 (1):131-156, (1993)
	A06	Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis," <i>The American Journal of Medicine</i> , Vol. 95 (suppl. 2A) pp.10S-18S, 1993.
	A07	Englehardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-Steroidal Anti-inflammatory Agent with Fovorable Gastrointestinal Tolerance," <i>Inflamm. Res.</i> 44:423-433 (1995).
	A08	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," <i>Brit. J. Rheumatology</i> 35 (suppl. 1):4-12, 1996.
	A09	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," <i>Brit. J. Rheumatology</i> 35 (suppl. 1): 68-77, 1996.
	A10	Wojtiluewski et al., "A Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," <i>Brit. J. Rheumatology</i> 35 (suppl. 1): 22-28, 1996
	A11	Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," <i>Inflammopharmacology</i> Vol 3(4) pp. 351-361 (1995)
	A12	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," <i>PNAS USA</i> Vol.91 pages 12013-12-17 (Dec. 1994)
	A13	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," <i>Drug Safety</i> Vol. 15(4), pp. 249-260 (Oct. 1996)
	A14	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," <i>Arzneim-Forsch./Drug res.</i> 42 (II), Nr. 7, pp. 935-944 (1992)
	A15	Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); December 1, 1998; obtained from http://www.citizen.org/publications/print_release.cfm?ID=6653 on October 28, 2008.
	A16	NDA 020938 Approval letter and label April 13, 2000; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A17	NDA 20-938 Medical Review, completed August 31, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A18	NDA 20-938 Pharmacology Review(s), completed September 17, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A19	NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A20	NDA 20-938 Correspondence, 1998-1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A21	NDA 20-938 Administrative Documents, 1998; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A22	NDA 20-938 Chemistry Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A23	NDA 20-938 Microbiology Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 200.1079CON5	APPLICATION NO 10/057,630
	APPLICANT Ronald M. BURCH et al.	
	FILING DATE January 25, 2002	GROUP 1639

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	A24	NDA 20-938 Statistical Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
	A25	Therapeutics Initiative, February 1995
	A26	Therapeutics Initiative, January 1997
	A27	Therapeutics Initiative, January/February 2001
	A28	Prescribing Points, volume 8.4, June 1999
	A29	Lichtblau, L. et al., "Pharmacologic management of cancer pain in rural Minnesota," <i>J Pain Symptom Manage</i> , Vol. 12, No. 5, p. 283-9, 1996.
	A30	Wollheim, F.A., "Current pharmacological treatment of osteoarthritis," <i>Drugs</i> , Vol. 52, Suppl. 3, p. 27-38, 1996.
	A31	Furst, D.E., "Meloxicam: selective COX-2 inhibition in clinical practice," <i>Semin Arthritis Rheum</i> , Vol. 26, No. 6, Suppl. 1, pp. 21-7, 1997.
	A32	Capasso, Anna et al. "Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum" <i>European Journal of Pharmacology</i> Vol. 330 (1997), pp. 199-204

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	